bioAffinity Technologies, Inc. 8-K

What Happened
bioAffinity Technologies, Inc. (BIAF) filed an 8‑K on February 19, 2026 (Item 8.01) to announce a press release describing a new clinical case study. The case study reports that the company’s CyPath® Lung test helped determine the appropriate treatment for a 79‑year‑old female patient who had a suspicious finding on a low‑dose computed tomography (LDCT) scan.

Key Details

• Filing date: February 19, 2026; item reported: 8.01 Other Events.
• Patient: 79‑year‑old female with a suspicious LDCT lung finding; CyPath Lung used to guide treatment decision.
• The press release announcing the case study is attached to the 8‑K as Exhibit 99.1.
• Company: bioAffinity Technologies, Inc., a Delaware corporation (ticker: BIAF).

Why It Matters
This announcement provides an example of CyPath Lung being used in a real clinical situation to inform a treatment decision, which may be relevant for investors watching clinical validation and commercial adoption of the company’s diagnostic technology. The 8‑K and attached press release give investors a concrete, dated example of product usage without offering new financial data or forward guidance.